Table 2. The characteristics of all the studies included.
| First author(year) | Patient characteristics | Study characteristics | Imaging characteristics | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (yr) | PSA (ng/ml) | Gleason score | No.of patients | Reading (retrospective/prospective) | Patient enrollment | Analysis | Readers | Blinding | Prior prostate Bx |
Reference test |
Tesla | ERC | Study population | ||||
| Median or mean (n) | Range | Median or mean (n) | Range | Median or mean (n) | Range | ||||||||||||
| Abd-Alazeez (2013) | 64 (Median) | 39–75 | 10(Median) | 4–23 | NR | 6–8 | 54 | NR | NR | Biopsy | 8 | Y | TRUS Bx- | TPM | 1.5T, 3T | N | Single center |
| Aydin (2012) | 69 (mean) | 54–82 | 70.6(Median) | 1.6–139.53 | 7(mean) | 5–10 | 40 | prospective | consecutive | Biopsy | 2 | NR | NR | TRUS or RP | 1.5T | N | Single center |
| Baur (2014) | 66 (mean) | 54–78 | 10(Median) | 2.9–65.2 | NR | 6–10 | 55 | retrospective | NR | Biopsy | 2 | NR | 54 patients TRUS Bx- | MR-TRUS-fusion Bx | 1.5T | N | Single center |
| Chabanova (2011) | 64.18 (mean) | 51–74 | 7(mean) | 1.3–28 | NR | 4–9 | 43 | NR | consecutive | Biopsy | 2 | Y | NR | TRUS | 1.5T | Y | Single center |
| Iwazawa (2011) | 68.8 (mean) | 41–86 | 20.51(mean) | 4.04–568.5 | 7.04(mean) | 6–9 | 178 | retrospective | consecutive | Biopsy | 2 | Y | NR | TRUS | 1.5T | N | Single center |
| Kim CK (2006) | 73 (mean) | 58–71 | 16.9(mean) | 0.6–55.4 | NR | NR | 20 | NR | consecutive | Biopsy | 2 | NR | NR | TRUS | 3T | N | Single center |
| Kim JK (2005) | 64.9 (mean) | 49–75 | NR | 2.6–43.5 | NR | 6–10 | 53 | retrospective | NR | Biopsy | 4 | Y | NR | RP | 1.5T | N | Single center |
| Kitajima (2010) | 69 (Median) | 56–84 | 11.1(Median) | 4.2–112.1 | NR | NR | 53 | retrospective | consecutive | Biopsy | 2 | Y | NR | TRUS | 3T | Y | Single center |
| Kozlowski (2010) | 61.7 (mean) | 38–72 | 8.5(mean) | 0.94–15 | NR | 6–9 | 25 | prospective | consecutive | Biopsy | NR | NR | no prior treatment | MR-TRUS-guide Bx | 3T | Y | Multicenter |
| Reisaeter (2015) | 60.7 (mean) | 42.9–70.3 | 11.6(mean) | 3–81.4 | NR | 6–9 | 63 | retrospective | consecutive | Biopsy | 3 | NR | NR | WMS | 1.5T | Y | Single center |
| Portalez (2010) | 62.4 (mean) | 49–76 | 9.16(mean) | 1.6–25 | NR | NR | 68 | prospective | consecutive | Biopsy | 1 | NR | TRUS Bx- | TRUS | 1.5T | Y | Single center |
| Puech (2009) | 62 (mean) | 46–76 | 8.15(mean) | 1.45–26.4 | NR | NR | 83 | NR | consecutive | Biopsy | 2 | NR | DRE+ | WMS | 1.5T | N | Single center |
| Rosenkrantz(2012) | 63 (mean) | 48–85 | 7.4(mean) | 1–40 | NR | 5–7 | 42 | retrospective | NR | Biopsy/ Patient |
2 | NR | 29 patients TRUS Bx- | TRUS | 3T | N | Single center |
| Rosenkrantz(2015) | 62 (mean) | 46–81 | 6.9(mean) | NR | NR | 6–9 | 106 | retrospective | NR | Biopsy | 3 | Y | NR | RP | 3T | N | Single center |
| Tamada (2011) | 70 (mean) | 40–84 | 6.84(mean) | 4.06–9.94 | 7(Median) | 6–10 | 50 | retrospective | NR | Biopsy/ Patient |
2 | Y | NR | TRUS | 1.5T | N | Single center |
| Tamada (2008) | 71 (mean) | 62–84 | 16.9(mean) | 2.98–125 | 7(Median) | 5–10 | 40 | retrospective | NR | Biopsy | 2 | NR | NR | TRUS | 1.5T | N | Single center |
| Turkbey(2011) | 60.2 (mean) | 49–75 | 6.37(mean) | 2.3–23.7 | 7(Median) | 6–9 | 45 | prospective | consecutive | Biopsy | 2 | NR | NR | WMS | 3T | Y | Single center |
| Van den Bergh(2013) | 65 (Median) | 49–74 | 10.4(Median) | 1.5–70.9 | NR | 6–10 | 73 | prospective | consecutive | Biopsy | 1 | Y | NR | RP | 1.5T | N | Single center |
| Weidner (2011) | 63.5 (Median) | 40–79 | NR | 4.25–137 | NR | 5–8 | 16 | retrospective | NR | Biopsy | 2 | Y | NR | RP | 1.5T | Y | Single center |
| Yoshizako(2008) | 65 (Median) | 52–76 | NR | NR | NR | 6–9 | 35 | retrospective | NR | Biopsy | 2 | Y | NR | RP | 1.5T | N | Single center |
| Yu(2008) | 62.5 (Median) | 46–75 | 11.2(mean) | 5–39.1 | NR | NR | 21 | retrospective | consecutive | Biopsy | 2 | Y | NR | RP | 3T | N | Single center |
| Zhang(2014) | 75 (mean) | 50–83 | 14.19(median) | 4.59–470.3 | NR | 7–9 | 75 | NR | consecutive | Patient | 2 | Y | NR | TRUS | 3T | N | Single center |
| Ferda(2013) | NR | 47–79 | NR | 4.2–123 | NR | NR | 164 | prospective | NR | Patient | NR | NR | NR | TRUS | 3T | N | Single center |
| Vilanova(2011) | 63.5 (mean) | 43–87 | 7.4 (Median) |
4–17.20 | 7(Median) | 5–8 | 70 | retrospective | NR | Patient | 3 | Y | NR | TRUS | 1.5T | Y | Multicenter |
| Watanabe(2010) | 72.2 (mean) | 55–88 | 6.7(Median) | 2.5–33.53 | 6.4(Mean) | 4–9 | 43 | retrospective | consecutive | Patient | 1 | NR | NR | TRUS/RP | 1.5T | N | Multicenter |
| Haffner(2011) | 64 (Median) | 47–83 | 6.75(Median) | 0.18–100 | NR | NR | 555 | NR | consecutive | Patient | NR | NR | NR | TRUS | 1.5T | N | Single center |
Abbreviations: NR: not reported; ERC: endorectal coil; TRUS: transrectal ultrasound; Bx: biopsy; Bx-: negative TRUS-guided Bx; TPM: transperineal template prostate mapping; WMS: whole-mount section histopathology; DRE+: positive digital rectal examination; RP: radical prostatectomy.